Enzo Biochem (ENZ) Posts Narrower than Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ENZ Hot Sheet
Price: $0.31 --0%
Financial Fact:
Selling, general, and administrative: 11.47M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Selling, general, and administrative: 11.47M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Enzo Biochem, Inc. (NYSE: ENZ) reported Q3 loss of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $25.8 million versus the consensus estimate of $24.77 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Grainger (GWW) Tops Q3 EPS by 87c ; Offers Guidance
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
